Project Grant SB1HL184388
Award Date 8/10/26
Completion Date 7/31/27
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- Starlight Cardiovascular, Inc. was awarded a $1,477,713 Project Grant from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program to develop the first FDA-approved stent designed specifically for ductus arteriosus. The ductus arteriosus is a natural blood vessel that remains open in infants born with certain congenital heart defects; currently there are no stents approved for this use, forcing clinicians to repurpose adult coronary stents which have a high 47%...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Heart, Lung, and Blood Institute awarded Pediastent LLC $1.472 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a first-in-baby clinical study of the CARDIAZN bioresorbable stent, a zinc-alloy device designed to treat pulmonary artery stenosis and coarctation of the aorta in small children. The CARDIAZN stent maintains peak radial strength for approximately six months post-implantation to provide structural support to diseased...
- The National Heart, Lung, and Blood Institute awarded Minnesota Healthsolutions Corporation $329,537 on August 15, 2026, to develop a novel balloon angioplasty inflation device under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will design and evaluate a prototype inflation device intended to improve safety and efficacy during percutaneous balloon angioplasty by accounting for molecular composition and elasticity differences in arterial tissue. Current market devices...
- The National Heart, Lung, and Blood Institute awarded Lazarus 3D, Inc. $400,016 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate PRE-SURE-CHD, a patient-specific preoperative surgical rehearsal and planning platform for congenital heart defects using 3D printing technology. The project develops synthetic materials that replicate the mechanical properties of cardiac tissue, creates patient-specific 3D-printed prototypes informed by CT...
- The National Heart, Lung, and Blood Institute awarded the University of California Irvine $760,016 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and advance the IRIS Valve, a growth-accommodating, transcatheter pulmonary valve system designed for young children with congenital heart defects. The IRIS Valve addresses a critical clinical gap: current transcatheter pulmonary valve replacement (TPVR) devices and surgically implanted valves cannot...
- The National Heart, Lung, and Blood Institute awarded Perfusion Solutions Inc. $217,013 on August 1, 2026, to develop a bearingless, fail-safe pump for patients with single ventricle physiology following Fontan surgical palliation under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds Phase I research to design and develop a bearingless motor integrated into a centrifugal pump rotor, with the pump's stator incorporating the motor stator. The device is engineered to...